One of the Catalent Inc. factories Novo Nordisk A/S is buying to boost supply of its popular weight-loss injection Wegovy isn’t meeting safety and quality standards, according to an inspection document.
Inspectors from the US Food and Drug Administration visited the Catalent plant in Bloomington, Indiana, in October and November and documented multiple instances of workers failing to ensure the quality and purity of drugs produced there, according to the 10-page document, obtained via a Freedom of Information request. It was also noted that a “pest” had been found somewhere on a manufacturing line handling syringes in June. The name ...
